Stefano Fanti, MD, presented “Molecular Imaging and Prostate” during the 8th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on October 8, 2024.
How to cite: Fanti, Stefano. “Molecular Imaging and Prostate.” October 8, 2024. Accessed Feb 2025. https://grandroundsinurology.com/utility-of-micro-ultrasound-in-prostate-cancer-active-surveillance-1/
Molecular Imaging and Prostate – Summary
In this 10-minute presentation, Stefano Fanti, MD, provides an expert overview of molecular imaging in prostate cancer, focusing on the transformative role of PSMA PET. He begins by emphasizing the growth of PET imaging, particularly PSMA-based tracers, as the preferred method for prostate cancer in clinical settings.
Dr. Fanti highlights landmark studies, including data demonstrating the superiority of gallium-labeled PSMA over older tracers like choline. He discusses the global availability of PSMA PET, showcasing its integration into clinical practice worldwide. He outlines its primary indications, including staging high-risk patients, detecting biochemical recurrence, and therapy planning.
He references guidelines from leading organizations, including NCCN and ASCO, which support PSMA PET’s use over conventional imaging methods. Dr. Fanti reviews evidence from multicenter trials, illustrating its greater accuracy in detecting metastatic disease and influencing patient management. He describes PSMA PET as a game-changer that has revolutionized prostate cancer imaging, offering unparalleled utility in staging and recurrence detection.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Dr. Adam Kinnaird, MD, PhD, FRCSC is a surgeon and scientist, currently appointed as an assistant professor in the Department of Surgery in the Faculty of Medicine & Dentistry at University of Alberta in Edmonton, Alberta, Canada. Dr. Kinnaird also serves as the Chair of The Alberta Prostate Cancer Research Initiative (APCaRI) and the Frank and Carla Sojonky Chair in Prostate Cancer Research in the Division of Urology, Department of Surgery at theUniversity of Alberta.
Dr. Kinnaird completed his MD and urology residency at the University of Alberta, during which he was enrolled in the Clinician Investigator Program. He earned his PhD as a Vanier Scholar and was awarded the Governor General’s Gold Medal in research in 2018. He then completed a fellowship in imaging, targeted biopsy, and focal therapy for prostate cancer at UCLA.
He has published in high-impact journals such asNature Reviews Cancer,Cell, andEuropean Urologyand has been awarded funding from local, regional, and national grant competitions. Dr. Kinnaird is also a member of the Alberta Prostate Cancer Research Initiative (APCaRI) and Cancer Research Institute of Northern Alberta (CRINA). Currently, Dr. Kinnaird’s research interests include translational prostate cancer research with a focus on new drugs, technologies, and devices.
